|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RMND1 |
Gene summary for RMND1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RMND1 | Gene ID | 55005 |
| Gene name | required for meiotic nuclear division 1 homolog | |
| Gene Alias | C6orf96 | |
| Cytomap | 6q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | A0A087WXU0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55005 | RMND1 | GSM4909293 | Human | Breast | IDC | 7.74e-19 | 4.28e-01 | 0.1581 |
| 55005 | RMND1 | GSM4909304 | Human | Breast | IDC | 3.74e-10 | 3.80e-01 | 0.1636 |
| 55005 | RMND1 | GSM4909306 | Human | Breast | IDC | 7.55e-25 | 6.48e-01 | 0.1564 |
| 55005 | RMND1 | GSM4909308 | Human | Breast | IDC | 6.82e-03 | 1.88e-01 | 0.158 |
| 55005 | RMND1 | GSM4909311 | Human | Breast | IDC | 4.37e-02 | 1.18e-01 | 0.1534 |
| 55005 | RMND1 | GSM4909312 | Human | Breast | IDC | 3.52e-03 | 2.55e-01 | 0.1552 |
| 55005 | RMND1 | GSM4909319 | Human | Breast | IDC | 4.33e-04 | 7.12e-03 | 0.1563 |
| 55005 | RMND1 | M1 | Human | Breast | IDC | 7.34e-12 | 4.50e-01 | 0.1577 |
| 55005 | RMND1 | DCIS2 | Human | Breast | DCIS | 1.97e-23 | 4.23e-02 | 0.0085 |
| 55005 | RMND1 | LZE4T | Human | Esophagus | ESCC | 1.70e-03 | 1.20e-01 | 0.0811 |
| 55005 | RMND1 | LZE7T | Human | Esophagus | ESCC | 1.62e-04 | 2.35e-01 | 0.0667 |
| 55005 | RMND1 | LZE8T | Human | Esophagus | ESCC | 4.41e-02 | 7.81e-02 | 0.067 |
| 55005 | RMND1 | LZE22T | Human | Esophagus | ESCC | 1.40e-06 | 2.77e-01 | 0.068 |
| 55005 | RMND1 | LZE24T | Human | Esophagus | ESCC | 2.08e-11 | 2.34e-01 | 0.0596 |
| 55005 | RMND1 | LZE21T | Human | Esophagus | ESCC | 9.73e-05 | 2.68e-01 | 0.0655 |
| 55005 | RMND1 | P1T-E | Human | Esophagus | ESCC | 1.64e-05 | 2.10e-01 | 0.0875 |
| 55005 | RMND1 | P2T-E | Human | Esophagus | ESCC | 1.31e-14 | 2.92e-01 | 0.1177 |
| 55005 | RMND1 | P4T-E | Human | Esophagus | ESCC | 1.26e-16 | 3.61e-01 | 0.1323 |
| 55005 | RMND1 | P5T-E | Human | Esophagus | ESCC | 4.50e-13 | 2.77e-01 | 0.1327 |
| 55005 | RMND1 | P8T-E | Human | Esophagus | ESCC | 2.02e-12 | 1.92e-01 | 0.0889 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000641714 | Breast | IDC | regulation of translation | 74/1434 | 468/18723 | 1.67e-09 | 1.53e-07 | 74 |
| GO:004572714 | Breast | IDC | positive regulation of translation | 33/1434 | 136/18723 | 1.92e-09 | 1.73e-07 | 33 |
| GO:003425014 | Breast | IDC | positive regulation of cellular amide metabolic process | 35/1434 | 162/18723 | 1.63e-08 | 1.16e-06 | 35 |
| GO:00325432 | Breast | IDC | mitochondrial translation | 13/1434 | 76/18723 | 4.81e-03 | 3.67e-02 | 13 |
| GO:000641724 | Breast | DCIS | regulation of translation | 72/1390 | 468/18723 | 2.46e-09 | 2.17e-07 | 72 |
| GO:004572724 | Breast | DCIS | positive regulation of translation | 32/1390 | 136/18723 | 3.56e-09 | 3.10e-07 | 32 |
| GO:003425023 | Breast | DCIS | positive regulation of cellular amide metabolic process | 34/1390 | 162/18723 | 2.60e-08 | 1.73e-06 | 34 |
| GO:003254311 | Breast | DCIS | mitochondrial translation | 13/1390 | 76/18723 | 3.70e-03 | 2.99e-02 | 13 |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:003254314 | Esophagus | ESCC | mitochondrial translation | 68/8552 | 76/18723 | 1.02e-15 | 6.86e-14 | 68 |
| GO:0045727111 | Esophagus | ESCC | positive regulation of translation | 107/8552 | 136/18723 | 2.79e-15 | 1.68e-13 | 107 |
| GO:0034250111 | Esophagus | ESCC | positive regulation of cellular amide metabolic process | 123/8552 | 162/18723 | 3.32e-15 | 1.93e-13 | 123 |
| GO:00701292 | Esophagus | ESCC | regulation of mitochondrial translation | 22/8552 | 24/18723 | 2.82e-06 | 3.21e-05 | 22 |
| GO:00621252 | Esophagus | ESCC | regulation of mitochondrial gene expression | 24/8552 | 28/18723 | 1.37e-05 | 1.25e-04 | 24 |
| GO:00701312 | Esophagus | ESCC | positive regulation of mitochondrial translation | 14/8552 | 15/18723 | 1.47e-04 | 9.85e-04 | 14 |
| GO:000641722 | Liver | HCC | regulation of translation | 287/7958 | 468/18723 | 8.79e-17 | 8.08e-15 | 287 |
| GO:01400531 | Liver | HCC | mitochondrial gene expression | 82/7958 | 108/18723 | 1.49e-12 | 7.20e-11 | 82 |
| GO:00325431 | Liver | HCC | mitochondrial translation | 62/7958 | 76/18723 | 2.95e-12 | 1.34e-10 | 62 |
| GO:004572712 | Liver | HCC | positive regulation of translation | 97/7958 | 136/18723 | 8.51e-12 | 3.55e-10 | 97 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RMND1 | SNV | Missense_Mutation | c.20G>A | p.Arg7Lys | p.R7K | Q9NWS8 | protein_coding | tolerated_low_confidence(0.21) | benign(0.027) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RMND1 | SNV | Missense_Mutation | c.103G>A | p.Glu35Lys | p.E35K | Q9NWS8 | protein_coding | tolerated_low_confidence(0.26) | benign(0) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| RMND1 | SNV | Missense_Mutation | c.163N>G | p.Pro55Ala | p.P55A | Q9NWS8 | protein_coding | tolerated_low_confidence(0.22) | benign(0.211) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| RMND1 | SNV | Missense_Mutation | c.275N>G | p.Lys92Arg | p.K92R | Q9NWS8 | protein_coding | tolerated(0.29) | benign(0) | TCGA-E2-A15D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| RMND1 | SNV | Missense_Mutation | rs138900217 | c.329N>C | p.Lys110Thr | p.K110T | Q9NWS8 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| RMND1 | SNV | Missense_Mutation | novel | c.565N>G | p.Gln189Glu | p.Q189E | Q9NWS8 | protein_coding | tolerated(0.33) | benign(0.013) | TCGA-GM-A3NW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| RMND1 | insertion | Frame_Shift_Ins | novel | c.881_882insAGAGAATATACAATTTCTACCTAATAAAATTATGAAATTTC | p.Asp294GlufsTer16 | p.D294Efs*16 | Q9NWS8 | protein_coding | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| RMND1 | insertion | Nonsense_Mutation | novel | c.320_321insCTTTGAAGCCTAATAAATATCCAAAG | p.Thr108PhefsTer4 | p.T108Ffs*4 | Q9NWS8 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| RMND1 | SNV | Missense_Mutation | c.49N>C | p.Ser17Pro | p.S17P | Q9NWS8 | protein_coding | tolerated_low_confidence(0.06) | benign(0) | TCGA-FU-A23L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RMND1 | SNV | Missense_Mutation | novel | c.242C>A | p.Ser81Tyr | p.S81Y | Q9NWS8 | protein_coding | tolerated_low_confidence(0.18) | benign(0) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |